Role of phosphatidylcholine-DHA in preventing APOE4-associated Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review and mechanistic hypothesis paper with no primary empirical data.
PubMed 30289748 · doi:10.1096/fj.201801412R
What was done
This paper is a narrative review and theoretical proposal evaluating why APOE4 allele carriers may respond favorably to fish intake but poorly to standard docosahexaenoic acid (DHA) fish oil supplements in preventing Alzheimer's disease.
What was found
The abstract provides no empirical data, statistical measures, or sample sizes. It outlines a mechanistic hypothesis: fish contains DHA primarily in phospholipid form, which is metabolized to lysophosphatidylcholine DHA (DHA-lysoPC) and transported across the blood-brain barrier (BBB) inner leaflet via the Mfsd2a transporter. In contrast, standard fish oil supplements yield free DHA, which depends on passive diffusion across the BBB outer membrane leaflet. The author hypothesizes that APOE4 carriers experience outer BBB membrane leaflet breakdown, impairing free DHA uptake while leaving DHA-lysoPC transport functional.
Why it matters
If validated, this hypothesis provides a biological rationale for discordant findings in omega-3 supplementation trials and suggests that phospholipid-bound DHA formulations could be specifically targeted to APOE4 carriers at risk for Alzheimer's disease.
Limits
The abstract presents purely theoretical, mechanism-based reasoning with no primary laboratory, animal, or human clinical trial data. No quantitative effect sizes, clinical outcomes, or controlled tests of the proposed transport mechanism are reported.
Cited by
- supports Dietary fish consumption protects APOE4 carriers against Alzheimer's disease, whereas isolated DHA supplementation does not show the same protective benefit in APOE4 carriers.